CD79A and lobular neoplasia: Preclinically, its dual blockade achieves superior suppression of immunoglobulin-secreting cells compared to selective BLyS inhibition, potentially offering enhanced control over APRIL-driven IgA/IgG production and plasma cell longevity – key factors in LN pathogenesis.